Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.75, for a total transaction of $936,892.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Thursday, January 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $51.71, for a total transaction of $973,802.72.
  • On Monday, December 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $55.40, for a total transaction of $1,043,292.80.

Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) opened at $54.06 on Thursday. Seattle Genetics, Inc. has a 1 year low of $45.31 and a 1 year high of $71.32. The firm has a market cap of $7,780.00, a PE ratio of -60.74 and a beta of 2.08.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. The company had revenue of $129.61 million for the quarter, compared to analyst estimates of $123.99 million. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 33.36%. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) EPS. analysts anticipate that Seattle Genetics, Inc. will post -1.59 EPS for the current year.

SGEN has been the subject of a number of analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a report on Thursday, October 26th. Cantor Fitzgerald set a $50.00 price target on shares of Seattle Genetics and gave the company a “hold” rating in a report on Monday, January 8th. JPMorgan Chase & Co. raised shares of Seattle Genetics from a “neutral” rating to an “overweight” rating and set a $60.00 price target for the company in a report on Wednesday. Morgan Stanley increased their price target on shares of Seattle Genetics from $64.00 to $69.00 and gave the company an “overweight” rating in a report on Tuesday, October 31st. Finally, Royal Bank of Canada increased their price target on shares of Seattle Genetics from $68.00 to $69.00 and gave the company an “outperform” rating in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $64.25.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its position in shares of Seattle Genetics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 299 shares during the period. Eqis Capital Management Inc. increased its position in shares of Seattle Genetics by 3.6% during the fourth quarter. Eqis Capital Management Inc. now owns 26,087 shares of the biotechnology company’s stock worth $1,396,000 after acquiring an additional 916 shares during the period. JGP Global Gestao de Recursos Ltda. increased its position in shares of Seattle Genetics by 4.9% during the third quarter. JGP Global Gestao de Recursos Ltda. now owns 20,603 shares of the biotechnology company’s stock worth $1,121,000 after acquiring an additional 969 shares during the period. Advisors Asset Management Inc. increased its position in shares of Seattle Genetics by 8.7% during the third quarter. Advisors Asset Management Inc. now owns 12,663 shares of the biotechnology company’s stock worth $689,000 after acquiring an additional 1,012 shares during the period. Finally, Amalgamated Bank increased its position in shares of Seattle Genetics by 5.8% during the fourth quarter. Amalgamated Bank now owns 19,142 shares of the biotechnology company’s stock worth $1,024,000 after acquiring an additional 1,043 shares during the period. 91.60% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://theolympiareport.com/2018/02/15/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-18832-shares.html.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.